The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes: an examination of the available evidence
Affiliation
The University of Manchester, Faculty of Biology, Medicine and Health Department of EndocrinologyIssue Date
2021
Metadata
Show full item recordAbstract
Purpose of review: Coronavirus Disease 2019 (COVID19) has caused significant global morbidity and mortality, especially in persons with underlying cardiovascular disease. There have been concerns that lipid-lowering therapy (LLT) increases angiotensin-converting enzyme 2 levels. Conversely, pleiotropic effects of statins can theoretically protect against severe COVID19 infection, supporting evidence from other respiratory illnesses in which statin use probably confers benefit. Recent findings: There is an abundance of studies that show that statins are safe and potentially protect against severe COVID19 infection (critical illness and death), even when adjustment for potential confounders is undertaken. However, the evidence is limited to retrospective cohorts. The benefit for patients with diabetes is less clear. There is a paucity of evidence for other LLT agents. Available clinical guidelines recommend the ongoing use of LLT in patients with COVID19 (unless specifically contra-indicated) and the data from available studies support these. Summary: In patients with COVID19 infection, LLT should be continued. However, the current findings need substantiating in larger prospective clinical studies with specific examination of the possible mechanisms by which LLT confers benefit from COVID19.Citation
Adam S, Ho JH, Bashir B, Iqbal Z, Ferdousi M, Syed AA, et al. The impact of atherosclerotic cardiovascular disease, dyslipidaemia and lipid lowering therapy on Coronavirus disease 2019 outcomes: an examination of the available evidence. Current Opinion in Lipidology . 2021 Jun 9;32(4):231–43.Journal
Current Opinion in LipidologyDOI
10.1097/mol.0000000000000763PubMed ID
34116544Additional Links
https://dx.doi.org/10.1097/mol.0000000000000763Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1097/mol.0000000000000763
Scopus Count
Collections
Related articles
- Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor.
- Authors: Essop MR, Seedat F, Raal FJ
- Issue date: 2023 Nov 6
- The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
- Authors: Tan NC, Goh CC, Goh SC, Koh YL, Koh KH
- Issue date: 2016 Dec
- Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
- Authors: Shaik A, Kosiborod M, de Lemos JA, Gao Q, Mues KE, Alam S, Bhatt DL, Cannon CP, Ballantyne CM, Rosenson RS, GOULD Investigators
- Issue date: 2022 Dec
- Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
- Authors: Tenenbaum A, Fisman EZ, Motro M, Adler Y
- Issue date: 2008
- A Clinical Guide to Combination Lipid-Lowering Therapy.
- Authors: Russell C, Sheth S, Jacoby D
- Issue date: 2018 Mar 7